alexa Construction, Expression And Characterization Of A Cancer-specific Fusion Protein Targeting CD22 In B-cell Malignancies
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

Joint Event on 15th World Congress on Biotechnology And Biotech Industries Meet and 2nd International Conference on Enzymology and Molecular Biology
March 20-21, 2017 Rome, Italy

Solmaz Agha Amiri, Najmeh Zarei, Dorsa Khorasanizadeh, Elahe Aminelahi, Soraya Shahhosseini and Vahid Khalaj
Shahid Beheshti University of Medical Sciences, Iran
Pasteur Institute of Iran, Iran
Posters & Accepted Abstracts: J Biotechnol Biomater
DOI: 10.4172/2155-952X.C1.071
Abstract
Dual-function proteins are a new class of therapeutics that composed of an antibody or antibody fragment linked to a cytotoxic molecule to facilitate the targeted delivery and destruction of malignant cells. CD22 is a highly internalizing B-cell specific surface antigen which overexpressed in 60%-80% of different types of B-cell malignancies. Therefore, anti-CD22 antibodies are ideal candidates for targeted intracellular delivery of antitumor agents. Apoptin is a small 13KDa protein which can induce apoptosis in tumor and transformed cells but not in normal cells. Hence, the apoptin protein can be used as a toxic moiety in development of cancer -specific fusion proteins. In this study, we generated a novel dual function protein by fusing apoptin to the C-terminus of a humanized anti CD-22 scFv; the anti-CD22 scFv portion of the protein targets the whole molecule to the tumors, while apoptin executes specific killing functions. Using the routine molecular methods, the recombinant anti-CD22 scFv-apoptin protein was expressed in E. coli and then purified. The in-vitro binding analyses by immunofluorescence and flow cytometry demonstrated that the anti-CD22 scFv specifically bind to Raji CD22 positive cells and almost not to Jurkat CD22 negative cells. Evaluation of apoptotic property of anti-CD22 scFv-apoptin using flow cytometry showed that following specific binding of anti-CD22 scFv-apoptin, the protein induced apoptosis significantly in Raji cells (p<0.05). In conclusion, we have successfully produced functional anti-CD22 scFv-apoptin in E.coli. This recombinant protein may offer a new opportunity for the treatment of CD22+ B-cell malignancies.
Biography

Solmaz Agha Amiri is currently pursuing her PhD in the field of Pharmaceutical Biotechnology at Shahid Beheshti University of Iran. She has published five papers in reputed journals.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords